Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
An estimated 21 million American women experience BV
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
The investment will accelerate the overall Sarclisa development program
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Subscribe To Our Newsletter & Stay Updated
